contact[at]op2lysis.com

The company
The Technology
Products
Indications
News
Contact

Search for:

Orphan drug designation granted to OptPA for the treatment of non-traumatic spontaneous intracerebral hemorrhage by the European Commission

Home
Corporate
Orphan drug designation granted to OptPA for the treatment of non-traumatic spontaneous intracerebral hemorrhage by the European Commission

ODD-EMA Télécharger

Biotechnology company that researches and develops innovative medicines

Supported by

SItemap

Contact
home
Indications
Legal Notice
News
Products
The company
The Technology

Recent Posts

Retrospective – 2022 in a nutshell

January 24, 2023

The EIC Accelerator grant agreement has been signed by the European Innovation Council and provides €2.5M support to the O2L-001 development programme

December 07, 2022

Contact

FRANCE: 117 avenue Victor Hugo, 92100 Boulogne-Billancourt, France BELGIUM: Légia Park, Boulevard Patience et Beaujonc, 3, 4000 Liège, Belgium

Op2Lysis © 2022 All Rights Reserved – Legal notice – web agency : Bridge Communication